Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miguel Angel Arrabal-Polo has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond a negative PSMA PET: artificial intelligence for occult pN1 risk and extended pelvic lymph-node dissection selection in prostate cancer—a systematic scoping review

    by Patricia Rodríguez-Parras, Alberto Zambudio-Munuera, Irene Millán-Ramos, Francisco Gutiérrez-Tejero, Ana Morales-Martínez, Antonio Jiménez Pacheco, Miguel Ángel Arrabal Polo

  • Functional Outcomes of a Biofeedback-Guided Pelvic Floor Muscle Training Program Following Robot-Assisted Radical Prostatectomy

    by I. Millán-Ramos, A. Zambudio-Munuera, A. Donaire-Barrera, P. Rodríguez-Parras, M.I. Martinez-Sanchez, M. Arrabal-Martín, M.A. Arrabal-Polo

  • Open Access

    Cystinuria: Diagnosis, Medical and Surgical Management, and Emerging Therapies. A Narrative Review

    by Alberto Zambudio Munuera, Patricia Rodriguez Parras, Juan Antonio Galan Llopis, Feliciano Grases Freixedas, Maria del Carmen Cano Garcia, Miguel Arrabal-Martin, Miguel Angel Arrabal Polo

    Cystinuria is a hereditary aminoaciduria causing recurrent cystine nephrolithiasis, impaired quality of life and potential renal function decline. Despite established treatment guidelines, real-world data reveal a persistent gap between recommended targets and clinical outcomes. Preliminary data from the EUROCYS 2024 prospective European registry (269 patients, 29 centers, 8 countries) showed that only 16.3% of patients achieved the target urinary pH range, 55.2% remained above the conventional urinary cystine threshold of 250 mg/L, and approximately 39% experienced a new stone event within the preceding 12 months, despite follow-up in specialist centers. Discontinuation rates for available thiol drugs have been reported to reach 30– 50%. This narrative review, based on a structured non-systematic search of major databases and guideline repositories (2009– 2026), synthesizes current evidence on cystinuria diagnosis and management and appraises emerging adjunctive interventions. Next-generation sequencing-based genetic testing and the cystine capacity assay represent key recent advances in monitoring. Thulium fiber laser lithotripsy and miniaturized percutaneous approaches offer less traumatic surgical options in this high-burden population. Oral N-acetylcysteine has mechanistic plausibility and a favorable, well-characterized safety profile in other clinical settings, making it a rational candidate for formal prospective evaluation; however, robust clinical trial evidence in cystinuria using contemporary monitoring parameters is lacking. Current standard treatment remains insufficient for a substantial proportion of patients, underscoring the need to evaluate accessible adjunctive therapies with defined mechanisms and measurable outcomes.

  • Resultados funcionales de un programa de entrenamiento del suelo pélvico con biofeedback tras prostatectomía radical asistida por robot

    by I. Millán-Ramos, A. Zambudio-Munuera, A. Donaire-Barrera, P. Rodríguez-Parras, M.I. Martinez-Sanchez, M. Arrabal-Martín, M.A. Arrabal-Polo


  • Value of PSA density in PI-RADS 3 lesions: a single-center retrospective observational study

    by Patricia Rodriguez-Parras, Alberto Zambudio-Munuera, Ana Donaire-Barrera, Yaiza Yañez-Castillo, Maria del Carmen Cano-Garcia, Miguel Arrabal-Martin, Miguel Angel Arrabal-Polo

    Purpose The aim of this study was to evaluate whether Prostate-specific antigen density (PSAD) improves risk stratification for clinically significant prostate cancer in patients with PI-RADS 3 lesions and to assess its potential role in reducing unnecessary biopsies. Methods A single-center retrospective observational study was conducted at Hospital Universitario Clínico San Cecilio (Granada, Spain) between January 2022 and December 2025. A total of 203 patients with a PI-RADS 3 lesion who underwent systematic and targeted biopsy were included. Clinically significant prostate cancer was defined as ISUP ≥ 2. Univariate analysis, logistic regression (age and PSAD ≥ 0.15 ng/mL/cc), ROC curve analysis, and diagnostic performance metrics for PSAD ≥ 0.15 were performed. Results Prostate cancer was detected in 73/203 patients (36%) and csPCa in 21/203 (10.3%). PSAD was higher in csPCa cases (0.17 vs 0.11; p = 0.001). PSAD ≥ 0.15 was independently associated with csPCa (OR 4.56; 95% CI 1.58–13.14; p = 0.005), as was age (OR 1.08 per year; p = 0.036). PSAD yielded an AUC of 0.722 and the combined age + PSAD model an AUC of 0.751. With PSAD ≥ 0.15, sensitivity was 76.2%, specificity 61.0%, and negative predictive value 95.7%. Conclusion In conclusion, PSAD provides clinical value for risk stratification in PI-RADS 3 lesions and may support biopsy avoidance strategies in selected patients.

  • Open Access

    Pulsed Thulium:YAG laser enucleation versus open simple prostatectomy for large-gland benign prostatic hyperplasia: a retrospective comparative observational study

    by Alberto Zambudio-Munuera, Santiago Chiva-San Román, Irene Millán-Ramos, Miguel Herráez-Marcos, Miguel Arrabal-Martín, Miguel A. Arrabal-Polo

    Background: Evidence on high-peak-power pulsed Thulium:YAG laser enucleation (p-ThuLEP) remains limited, particularly for large prostates. This study aimed to compare perioperative, functional, and safety outcomes between p-ThuLEP and open simple prostatectomy (OSP) in patients with large-gland benign prostatic hyperplasia (BPH). We compared early perioperative, functional, and bleeding-related outcomes between p-ThuLEP and OSP in patients with large-gland BPH. Methods: We conducted a retrospective comparative observational study including 98 consecutive patients with prostate volumes 80–150 mL treated between January 2023 and May 2025 in a tertiary academic center. Cases were selected in a 1:1 ratio to obtain comparable group sizes; no formal matching procedure was performed. The primary outcome was bleeding-related complications (transfusion and postoperative hematuria). Secondary outcomes included perioperative parameters and early functional results [International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), prostate-specific antigen (PSA)]. Multivariable logistic regression adjusted for prostate volume, anticoagulant use, and positive urine culture. Results: p-ThuLEP significantly reduced hospital stay [mean difference −3.04 days; 95% confidence interval (CI): −4.09 to −2.16; P=0.002] and catheterization time (mean difference −6.42 days; 95% CI: −7.85 to −4.73; P=0.001), as well as transfusion rates (0% vs. 12.2%, P=0.01). Both groups demonstrated comparable early improvements in IPSS and Qmax. In multivariable analysis, anticoagulant use independently predicted hematuria [odds ratio (OR) 9.39; 95% CI: 1.56–56.45; P=0.01], whereas surgical approach showed a strong but non-significant association (OR 5.84; 95% CI: 0.95–35.92; P=0.057). Prostate volume was not independently associated with bleeding events. Conclusions: In this real-world cohort of large prostates, no significant differences in early functional outcomes were detected between p-ThuLEP and OSP, while p-ThuLEP was associated with shorter hospitalization and lower transfusion rates. Given the retrospective design and short follow-up, these findings primarily reflect early perioperative and short-term results. p-ThuLEP may represent a minimally invasive option in experienced centers. Prospective studies are warranted to confirm long-term durability.

  • Open Access

    Real-World Predictors of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: The Emerging Role of the Urologist in Immuno-Oncology

    by Celia Abad Rodriguez-Hesles, Francisco Gutierrez-Tejero, Virginia Yuste-Mascarós, Alberto Zambudio-Munuera, Miguel Arrabal-Martin, Miguel Angel Arrabal-Polo

    Immunotherapy has transformed the treatment of metastatic renal cell carcinoma (mRCC), with urologists playing a central role in systemic treatment selection through multidisciplinary decision-making, patient selection, and treatment sequencing. Identifying predictors of response is essential to personalize therapy and improve outcomes. We conducted a retrospective, single-center study of 32 patients with mRCC who received immunotherapy: 15 received first-line nivolumab-ipilimumab, 3 pembrolizumab-axitinib, 13 second-line nivolumab, and 1 third-line nivolumab. Clinical, histological, and prognostic variables (International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), Meet-URO, FAN score), and blood biomarkers (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), eosinophil percentage) were assessed using Kaplan-Meier analysis with Log rank tests and Cox regression. Given the small sample size, results should be interpreted with caution. A total of 32 patients were included, with the majority classified as IMDC intermediate risk. The Meet-URO score showed superior prognostic value for overall survival compared with IMDC (median 21 vs. 1–2 months across groups; 95% CI 1.83–20.17; p=0.043). A post-treatment NLR below 2.44 predicted improved progression-free survival (median 17 vs. 7 months; 95% CI 7.4–26.2; p=0.014) and remained independently significant. Neither FAN score nor eosinophil percentage provided prognostic discrimination. No survival differences were observed between treatment lines. Cytoreductive nephrectomy (78%) was associated with longer progression-free survival (9 vs. 3 months; HR: 3.72, 95% CI 1.15–12.02; p=0.028) and overall survival (21 vs. 3 months; HR 4.03, 95% CI 1.14–14.19; p=0.030). Cytoreductive nephrectomy, early NLR, and the Meet-URO score may have potential value for risk stratification in patients with mRCC receiving immunotherapy. In a real-world urology-led setting, these factors may support clinical decision-making and treatment selection. These findings should be considered exploratory and hypothesis-generating, given the limited sample size, and warrant confirmation in larger prospective studies.

  • Open Access

    Distal Ureteral Stricture Secondary to Urolithiasis: Stepwise Endourological and Surgical Management with Ureteral Reimplantation and Drug-Coated Balloon Dilation (Optilume)

    by Patricia Rodriguez-Parras, Ana Morales-Martinez, Alberto Zambudio-Munuera, Miguel Arrabal-Martin, Miguel Angel Arrabal-Polo

    Introduction: Acquired ureteral stricture is an uncommon but clinically relevant complication, mainly associated with long-standing urolithiasis, chronic inflammatory processes, and repeated endourological procedures. Case presentation: We present the case of a 48-year-old woman with left distal ureteral stricture secondary to urolithiasis and repeated endourological procedures, with a complicated clinical course and progressive renal functional impairment. Despite stepwise management including balloon dilations, endoscopic incision, prolonged urinary diversion, and ultimately ureteral reimplantation with a psoas hitch, the patient developed restenosis of the ureteral neomeatus. Due to persistent obstruction, endoscopic dilation with a paclitaxel-coated balloon (Optilume®) was performed. Subsequent imaging demonstrated partial improvement in ureteral drainage and relative functional improvement of the left kidney. Conclusion: This case highlights the potential complementary role of drug-coated balloons in complex and refractory benign ureteral strictures, although the currently available evidence remains limited.

  • Open Access

    Testicular Plasmacytoma as the First Manifestation of Systemic Multiple Myeloma

    by Patricia Rodriguez-Parras, Alberto Zambudio-Munuera, Miguel Herraez-Marcos, Francisco Gutierrez-Tejero, Miguel Angel Arrabal-Polo

    Multiple myeloma is a hematological malignancy characterized by clonal proliferation of plasma cells, usually confined to the bone marrow. Extramedullary disease (EMD) occurs in 7–18% of patients during the disease course and is associated with poor prognosis. Among extramedullary sites, testicular involvement is extremely rare, with an incidence of less than 2%. We present a rare case of testicular plasmacytoma as the first manifestation of systemic multiple myeloma, highlighting its imaging features and clinical implications.